Venetoclax (Ven) is a selective small‐molecule inhibitor of BCL‐2 that exhibits antitumoral
activity against MM cells with t (11; 14) translocation. We evaluated the safety and efficacy of …

Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in
multiple myeloma (MM) cells, particularly in those harboring t (11; 14), which express high …

The antiapoptotic proteins BCL-2 and myeloid cell leukemia sequence 1 (MCL-1) promote
multiple myeloma (MM) cell survival. Venetoclax is a selective, orally bioavailable small …

8007 Background: bb2121 is a second-generation chimeric antigen receptor (CAR) T cell
therapy targeting B cell maturation antigen (BCMA) to redirect T cells to recognize and kill …

PURPOSE Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with
relapsed or refractory multiple myeloma (RRMM) with t (11; 14) translocation. Venetoclax …

Proteins in the antiapoptotic B-cell lymphoma 2 (BCL-2) family play a role in the
pathophysiology of multiple myeloma (MM). Venetoclax is a highly selective, potent, oral …

Despite advances in the treatment of multiple myeloma, the disease still remains incurable
for the majority of patients. The overexpression of anti-apoptotic proteins (ie, Bcl-2, Bcl-XL or …

Background Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces
apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has …

Apoptotic evasion has been postulated as one of the main mechanisms of multiple myeloma
(MM) cell survival. 1, 2 The intrinsic apoptotic pathway, tightly regulated by the BCL-2 protein …

Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, has
activity as monotherapy in multiple myeloma (MM). This phase 1/2 study investigated …